Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01438307 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT01438307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01438307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
September 30, 2015
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc, non-small cell lung cancer (nsclc), stage iv nsclc